The US Congress proposes a package of bills on drug pricing, including changes to the treatment of reverse payments, product hopping, sham petitions, and patent dancing

KEYWORDS
References

US Congress, Pallone Re-introduces Historic Prescription Drug Price Negotiation Legislation, Press release, 21 April 2021

US Congress, Bill to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes, Legislative proposal, 21 April 2021

US Congress, Bill to provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes, Legislative proposal, 21 April 2021

US Congress, Bill to amend title XVIII of the Social Security Act to require manufacturers of certain single-dose vial drugs payable under part B of the Medicare program to provide refunds with respect to amounts of such drugs discarded, and for other purposes, Legislative proposal, 21 April 2021

US Congress, Treating the Problem: Addressing Anticompetitive Conduct and Consolidation in Health Care Markets, 23 April 2021

What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new package of proposed bills, announced in connection with an April 2021 US House of Representatives Judiciary Antitrust Subcommittee hearing on drug prices, may indicate that federal lawmakers are turning their competition focus to the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.